{
    "clinical_study": {
        "@rank": "23327", 
        "arm_group": [
            {
                "arm_group_label": "Lactulose and Rifaximin Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day."
            }, 
            {
                "arm_group_label": "Rifaximin and Lactulose Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether taking Rifaximin (Xifaxan) in conjunction\n      with the use of nutritional concepts is effective in improving morbidity and quality of life\n      in cirrhotic patients suffering from hepatic encephalopathy (HE)."
        }, 
        "brief_title": "Quality of Life and Nutritional Improvements in Cirrhotic Patients", 
        "condition": [
            "Liver Cirrhosis", 
            "Hepatic Encephalopathy", 
            "Portal Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatic Encephalopathy", 
                "Hypertension", 
                "Hypertension, Portal", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Brain Damage, Chronic", 
                "Delirium", 
                "Encephalitis", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prevention of portal hypertension complications should be at the forefront. In doing so, the\n      end result will be an improvement in the multitude of morbidity and mortality issues. The\n      proposed prospective trial will compare patients with similar demographics and medical and\n      clinical settings utilizing standard of care therapy. Study subjects will be randomly\n      assigned into two treatment groups. Group one will receive Lactulose 30ml three times a day\n      as SOC and Rifaximin Placebo 550mg twice a day with nutritional supervision and group two\n      will receive Rifaximin 550mg twice per day as SOC and Lactulose placebo 30ml three times per\n      day with nutritional supervision."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female gender of Age 18 years or older\n\n          -  Liver cirrhosis defined as one or more of the following: Radio-graphically proven\n             portal hypertension (CT with nodular appearance) or Liver biopsy with cirrhosis\n\n          -  Model for End Stage Liver Disease (MELD) score < 20\n\n          -  Willingness to provide written informed consent, and participate in all study\n             requirements\n\n          -  Sodium greater than 130 meq/L\n\n          -  Conn Score < 2\n\n        Exclusion Criteria:\n\n          -  Active alcohol consumption\n\n          -  Serum total bilirubin level > 5 mg/dl\n\n          -  History of hepatocellular carcinoma (HCC) and malignancies other than basal cell\n             carcinoma of the skin\n\n          -  Pregnant or breastfeeding women\n\n          -  Subject has renal insufficiency requiring routine dialysis\n\n          -  Poorly controlled diabetes as defined by HgA1C > 10\n\n          -  Narcotic/psychotropic usage other than a stable dose of antidepressant and/or\n             methadone. Neurontin (gabapentin) and Lyrica (pregabalin) are permitted if the\n             subject has been on a stable dose for at least 2 months prior to the screening visit\n             and no change of dosing is expected throughout the length of the trial\n\n          -  Any of the following diagnoses:\n\n          -  HIV\n\n          -  Evidence of severe concomitant illness or any condition that makes them  unsuitable\n             for the study in the opinion of the investigator(s)\n\n          -  Subject has received an investigational drug within 30 days prior to   enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842113", 
            "org_study_id": "Rifaximin and Nutrition"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rifaximin and Lactulose Placebo", 
                "description": "Rifaximin 550mg by mouth twice a day", 
                "intervention_name": "Rifaximin", 
                "intervention_type": "Drug", 
                "other_name": "Xifaxan"
            }, 
            {
                "arm_group_label": "Lactulose and Rifaximin Placebo", 
                "description": "Lactulose 30ml by mouth three times a day", 
                "intervention_name": "Lactulose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Enulose", 
                    "Generlac", 
                    "Cholac", 
                    "Constulose", 
                    "Kristalose", 
                    "Laxilose", 
                    "Portalac", 
                    "Hepatalac", 
                    "Constilac"
                ]
            }, 
            {
                "arm_group_label": "Rifaximin and Lactulose Placebo", 
                "description": "Lactulose Placebo 30ml three times a day", 
                "intervention_name": "Lactulose Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lactulose and Rifaximin Placebo", 
                "description": "Rifaximin Placebo twice a day", 
                "intervention_name": "Rifaximin Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sugar Pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifaximin", 
                "Lactulose"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33606"
                }, 
                "name": "Tampa General Medical Group"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.", 
        "overall_official": {
            "affiliation": "Tampa General Medical Group", 
            "last_name": "Guy Neff, MD, MBA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Quality of Life will be determined by the Chronic Liver Disease Foundation Questionnaire (CLDQ), the Sleep Scale by Hays, R.D.&Stewart, A.L. and the Multidimensional Assessment of Fatigue (MAF) Scale and measured based upon Subjective Global Assessment (SGA).", 
                "measure": "Outcomes of Change in Quality of Life Assessment Between the Two Groups", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for 180 days"
            }, 
            {
                "description": "These outcomes will be determined as Body Composition Analysis via the Quadscan 4000 BIA device manufactured by Bodystat;calories burned, steps taken and levels of physical activity to sleep efficiency will be measured via the Bodymedia CORE Fit actigraph device and various standard of care laboratories.", 
                "measure": "Nutritional Improvement Between the Two Groups", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for 180 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842113"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tampa General Hospital", 
            "investigator_full_name": "Guy Neff, MD", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "These outcomes will be determined as Body Composition Analysis via the Quadscan 4000 BIA device manufactured by Bodystat;calories burned, steps taken and levels of physical activity to sleep efficiency will be measured via the Bodymedia CORE Fit actigraph device and various standard of care laboratories.", 
            "measure": "Markers of improvement in general health", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for 180 days"
        }, 
        "source": "Tampa General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tampa General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013", 
        "why_stopped": "PI Initiated study - PI left facility"
    }
}